PTK2 and neoplasm: Importantly, our in vivo experiments validated these findings, showing that combined FAK/RAF/MEK inhibition not only inhibited primary tumor growth but also significantly reduced the incidence of lung and brain metastases and prolonged overall survival in mouse models.